Lexatumumab (HGS-ETR 2) 是一种人源激动 TRAIL 受体 2 (TRAIL-R2, DR5, APO-2) IgG1 型单克隆抗体。Lexatumumab 在恶性间皮瘤中诱导细胞凋亡 (apoptosis)。Lexatumumab 可用于恶性胸膜间皮瘤 (MPM) 研究。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (lexatumumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (lexatumumab) is 99.04%, determined by SEC-HPLC.

Immobilized human TNFRSF10B/TRAILR2 / CD262, Fc Tag at 2 ug/mL can bind lexatumumab, EC50=0.03685 ug/mL.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.